Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Anemia, Refractory, with Excess of Blasts × Watchful Waiting × 30 days × Clear all

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 4 Prostatic Neoplasms 3 Oropharyngeal Neoplasms 2 Lung Neoplasms 2 Carcinoma, Renal Cell 2 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Stage I Mixed Cell Type Kidney Wilms Tumor 1 Retinoblastoma 1 Pleuropulmonary blastoma 1 Pelvic Neoplasms 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Melanoma 1 Lymphoma, Mantle-Cell 1 Leukemia, Myeloid, Acute 1 Epstein-Barr Virus Infections 1 Burkitt Lymphoma 1 Breast Neoplasms 1 Breast Carcinoma In Situ 1 Anus Neoplasms 1 Anatomic Stage I Breast Cancer AJCC v8 1 Anal Canal Carcinoma 1

Interventions

fludarabine 4 Mycophenolic Acid 4 Cyclophosphamide 4 fludarabine phosphate 3 Whole-Body Irradiation 3 Azacitidine 3 venetoclax 2 Vorinostat 2 Tacrolimus 2 Specimen Handling 2 Biopsy 2 decitabine and cedazuridine drug combination 1 cedazuridine 1 TAK-243 1 Stem Cell Transplantation 1 Sirolimus 1 Peripheral Blood Stem Cell Transplantation 1 Mesna 1 Melphalan 1 Lenalidomide 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Cyclosporins 1 Cyclosporine 1 Clofarabine 1 Busulfan 1 Bone Marrow Transplantation 1 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡